Chemical Engineering and Science
ISSN (Print): 2328-7381 ISSN (Online): 2328-7373 Website: http://www.sciepub.com/journal/ces Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
Chemical Engineering and Science. 2013, 1(1), 1-6
DOI: 10.12691/ces-1-1-1
Open AccessArticle

Quantitative Determination of Milnacipran by Simple Colorimetric Methods

Md. Mubarakunnisa1, Avula Prameela Rani1, Seelam Harika1 and Chandra Bala Sekaran2,

1University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar, India

2Department of Biotechnology, Jagarlamudi Kuppuswamy Choudary College, Guntur, India

Pub. Date: February 28, 2013

Cite this paper:
Md. Mubarakunnisa, Avula Prameela Rani, Seelam Harika and Chandra Bala Sekaran. Quantitative Determination of Milnacipran by Simple Colorimetric Methods. Chemical Engineering and Science. 2013; 1(1):1-6. doi: 10.12691/ces-1-1-1

Abstract

In the present study, two sensitive, precise and accurate spectrophotometric methods have been developed for the determination of milnacipran in bulk and capsule formulation. The first method is based on the reaction of milnacipran with ninhydrin in N,N'-dimethylformamide medium at 80°C temperature to form a colored Ruhemann's purple, which exhibits absorption maximum at 575nm. The second method is based on extraction of milnacipran into chloroform as ion-pair with bromothymol blue. The yellow colored ion-pair complex exhibits absorption maximum at 410nm. Beer’s law is obeyed in the concentration ranges 2.5-37.5μg/mL and 2-12μg/mL of milnacipran for methods I and II, respectively. The effect of experimental variables were investigated and optimized. The validation parameters like linearity, sensitivity, accuracy, precision and robustness were checked by following the ICH guidelines. The proposed methods were applied for the analysis of milnacipran in capsule formulation with good results.

Keywords:
milnacipran ninhydrin bromothymol blue Ruhemann's purple ion-pair complex

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 10

References:

[1]  Puozzo, C., Panconi, E. and Deprez, D, “Pharmacology and pharmacokinetics of milnacipran,” International Clinical Psychopharmacology, 17(Supp 1), S25-35, Jun.2002.
 
[2]  Moret, C., Chaverzon, M., Finberg, J.P. and Briley, M, “Biochemical profile of midalcipran (f2207), 1-Phenyl-1-diethyl-aminocarbonyl 2aminomethyl cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug,” Neuropharmacology, 24(12), 1211-1219, Dec.1985.
 
[3]  Briley, M., Prost, J.F. and Moret, C, “Preclinical pharmacology of milnacipran,” International Clinical Psychopharmacology, 11 (Suppl 4), 9-14, Sep.1996.
 
[4]  Vijaya Lakshmi M., Seshagiri Rao, J.V.L.N. and Ravikumar, B.V.N, “Development and validation of RP-HPLC method for the estimation of milnacipran tablet dosage forms,” International Journal of Research in Pharmacy and Chemistry, 1(1), 40-43, Jan-Mar. 2011.
 
[5]  Srinivasa Rao, M., Siva Ramakrishna, V., Vardhan, B.V.N. and Ramachandran, D, “A Validated RP-HPLC method for the estimation of milnacipran in tablet dosage forms,” International Journal of ChemTech Research, 3(3), 1501-1505, Jul-Sep. 2011.
 
[6]  Priti, J.M. and Deepak, M.K, “Development and validation of RP-HPLC method for determination of milnacipran hydrochloride in pharmaceutical formulations,” International Journal of Pharmacy and Pharmaceutical Sciences, 2 (Suppl), 137-141, Feb.2010.
 
[7]  Nadège, C. Karine, T., Receveur-Daurel, M., Le-Déodic, M., Le-bars, D., Nicholas, M. and Mathieu, M, “Quantification of eight new antidepressants and five of their active metabolites in whole blood by high-performance liquid chromatography-tandem mass spectrometry,” Journal of Analytical Toxicology, 31(6), 334-341, Jul-Aug. 2007.
 
[8]  Naresh, T., Shakil, S., Surendranath, R.V., Ravikiran, K. and Suresh, K, “Stability indicating U-HPLC method for milnacipran in bulk drugs and pharmaceutical dosage forms,” American Journal of Analytical Chemistry, 3(1), 40-49, Jan. 2012.
 
[9]  Deepak, M.K. and Priti, J.M, “Stability indicating HPTLC method for determination of milnacipran hydrochloride in pharmaceutical formulations,” Journal of Planar Chromatography, 24(5), 412-418, Oct. 2011.
 
[10]  Punit, B.P., Pragna, K.S., Rakshit, C.P., Bhavesh, S.B. and Arun, K, “Development and validation of UV spectrophotometric method for determination of milnacipran in bulk and pharmaceutical dosage form,” Eurasian Journal of Analytical Chemistry, 6(1), 53-58, Jan. 2011.
 
[11]  Sai Praveen, P., Sahiba, M., Rasool, Sk., Srinivasa Rao, T. and Prasad, D, “Spectrophotometric methods for the determination of milnacipran,” Asian Journal of Research in Chemistry, 4(1), 114-115, Jan. 2011.
 
[12]  Sai Praveen, P., Ramesh, P., Rasool, Sk. and Subramanyam, P, “Spectrophotometric methods for the determination of milnacipran,” Journal of Ultra Chemistry, 7(1), Jan. 2001.
 
[13]  Kumar, K.V. and Srivani, V, “Spectrophotometric methods for the determination of milnacipran in the formulation,” Research Journal of Pharmacy Technology, 4(8), 1250 -1252, Aug. 2011.
 
[14]  Raza, A., Ansari, T.M. and Rehman, A, “Spectrophotometric determination of lisinopril in pure and pharmaceutical formulations,” Journal of Chinese Chemical Society, 52(5), 1055-1059, Oct. 2005.
 
[15]  Rahman, N. and Azmi, S.N.H, “Spectrophotometric method for the determination of amlodipine besylate with ninhydrin in drug formulations,” II Farmaco, 56(10), 731-735, Sep. 2001.
 
[16]  Ansari, T.M., Raza, A. and Rehman, A, “Spectrophotometric Determination of Tranexamic Acid in Pharmaceutical Bulk and Dosage Forms,” Analytical Sciences, 21(9), 1133-1135, Sep. 2005.
 
[17]  Abdellatef, H.E. and Khalil, H.M, “Colorimetric determination of gabapentin in pharmaceutical formulation,” Journal of Pharmaceutical and Biomedical Analysis, 31(1), 209-214, Feb. 2003.
 
[18]  Elham, A.T. and Nadia, F.Y, Analytical spectrophotometric determination of some drugs for osteoporosis,” Chemical and Pharmaceutical Bulletin, 51(12), 1444-1447, Dec. 2003.
 
[19]  Kumar, A.V.V.N.K.S., Saradhi, S.V., Sekaran, C.B. and Reddy, T.V, “Spectrophotometric Analysis of Dutasteride in Pure and Tablet Dosage Forms,” Chemical Sciences Journal, CSJ-47, 2012.
 
[20]  Al-Ghannam, S.M, “A simple spectrophotometric method for the determination of β-blockers in dosage forms,” Journal of Pharmaceutical and Biomedical Analysis, 40(1), 151-156, Jan. 2006.
 
[21]  Erk, N, “Extractive spectrophotometric determination of atorvastatin in bulk and pharmaceutical formulations,” Analytical Letters, 36 (12), 2699-2711, Oct. 2003.
 
[22]  Cardoso, S.G., Ieggli, C.V.S. and Pomblum, S.C.G, “Spectrophotometric determination of carvedilol in pharmaceutical formulations through charge-transfer and ion-pair complexation reactions,” Die Pharmazie, 62(1), 34-37, Jan. 2007.
 
[23]  Validation of Analytical Procedures; Methodology, International Conference on Harmonization (ICH), Text and Methodology Q2(R 1), Complementary Guideline on Methodology dated 06 November 1996, incorporated in November 2005, London.